Overview of Tumor Heterogeneity in High-Grade Serous Ovarian Cancers.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
11 Oct 2023
Historique:
received: 15 09 2023
accepted: 10 10 2023
medline: 30 10 2023
pubmed: 28 10 2023
entrez: 28 10 2023
Statut: epublish

Résumé

Ovarian cancers encompass a group of neoplasms originating from germinal tissues and exhibiting distinct clinical, pathological, and molecular features. Among these, epithelial ovarian cancers (EOCs) are the most prevalent, comprising five distinct tumor histotypes. Notably, high-grade serous ovarian cancers (HGSOCs) represent the majority, accounting for over 70% of EOC cases. Due to their silent and asymptomatic behavior, HGSOCs are generally diagnosed in advanced stages with an evolved and complex genomic state, characterized by high intratumor heterogeneity (ITH) due to chromosomal instability that distinguishes HGSOCs. Histologically, these cancers exhibit significant morphological diversity both within and between tumors. The histologic patterns associated with solid, endometrioid, and transitional (SET) and classic subtypes of HGSOCs offer prognostic insights and may indicate specific molecular profiles. The evolution of HGSOC from primary to metastasis is typically characterized by clonal ITH, involving shared or divergent mutations in neoplastic sub-clones within primary and metastatic sites. Disease progression and therapy resistance are also influenced by non-clonal ITH, related to interactions with the tumor microenvironment and further genomic changes. Notably, significant alterations occur in nonmalignant cells, including cancer-associated fibroblast and immune cells, during tumor progression. This review provides an overview of the complex nature of HGSOC, encompassing its various aspects of intratumor heterogeneity, histological patterns, and its dynamic evolution during progression and therapy resistance.

Identifiants

pubmed: 37894756
pii: ijms242015077
doi: 10.3390/ijms242015077
pmc: PMC10606847
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Références

Int J Cancer. 2023 Jul 1;153(1):120-132
pubmed: 36883413
Cell Signal. 2020 Apr;68:109539
pubmed: 31935430
Clin Epigenetics. 2019 Nov 27;11(1):165
pubmed: 31775874
Gynecol Oncol. 2021 May;161(2):545-552
pubmed: 33674143
Mod Pathol. 2014 Oct;27(10):1405-11
pubmed: 24577588
Pathobiology. 2018;85(1-2):7-17
pubmed: 28750401
Lancet Oncol. 2011 Nov;12(12):1169-74
pubmed: 21742554
Br J Cancer. 2020 Sep;123(5):793-802
pubmed: 32555365
Sci Rep. 2019 Nov 29;9(1):17996
pubmed: 31784612
Trends Genet. 2021 Nov;37(11):1012-1027
pubmed: 34120771
Clin Epigenetics. 2021 Jul 22;13(1):142
pubmed: 34294135
Genes (Basel). 2021 Jul 20;12(7):
pubmed: 34356119
Genome Med. 2018 Oct 31;10(1):81
pubmed: 30382883
Cancer Res. 2023 May 2;83(9):1383-1385
pubmed: 37128849
Epigenetics. 2021 Nov;16(11):1201-1216
pubmed: 33289590
iScience. 2022 Feb 14;25(3):103923
pubmed: 35252817
Cancer Res. 2023 May 2;83(9):1503-1516
pubmed: 36787106
JAMA Netw Open. 2022 Oct 3;5(10):e2236626
pubmed: 36239936
Cancer Res. 2020 Oct 15;80(20):4335-4345
pubmed: 32747365
Gynecol Oncol. 2021 Jun;161(3):769-778
pubmed: 33714608
Br J Cancer. 2022 Jun;126(11):1570-1580
pubmed: 35017656
J Gynecol Oncol. 2023 Jul;34(4):e47
pubmed: 36807749
Nature. 2015 May 28;521(7553):489-94
pubmed: 26017449
Sci Rep. 2020 Feb 17;10(1):2757
pubmed: 32066851
PLoS Med. 2015 Feb 24;12(2):e1001789
pubmed: 25710373
Virchows Arch. 2016 Oct;469(4):371-84
pubmed: 27412632
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Clin Cancer Res. 2022 Aug 15;28(16):3590-3602
pubmed: 35675036
Turk Patoloji Derg. 2022;38(3):240-250
pubmed: 35147976
Front Endocrinol (Lausanne). 2023 Jun 19;14:1196094
pubmed: 37404304
Curr Oncol Rep. 2016 Jul;18(7):44
pubmed: 27241520
Front Med (Lausanne). 2018 Apr 06;5:85
pubmed: 29682505
Nat Rev Cancer. 2015 Nov;15(11):668-79
pubmed: 26493647
Am J Surg Pathol. 2016 Mar;40(3):404-9
pubmed: 26574845
Clin Epigenetics. 2021 Oct 13;13(1):190
pubmed: 34645493
Mol Cancer Res. 2018 Jul;16(7):1103-1111
pubmed: 29724815
J Immunother Cancer. 2022 Feb;10(2):
pubmed: 35115363
Br J Cancer. 2020 Jun;122(12):1803-1810
pubmed: 32249277
Gynecol Oncol. 2021 Oct;163(1):171-180
pubmed: 34275655
Nat Genet. 2020 Jun;52(6):582-593
pubmed: 32483290
Cancer Res. 2021 Nov 15;81(22):5706-5719
pubmed: 34561272
Cancer Drug Resist. 2022 Jun 01;5(2):451-458
pubmed: 35800377
Cancers (Basel). 2022 Jan 08;14(2):
pubmed: 35053468
Cell Rep Med. 2022 Dec 20;3(12):100856
pubmed: 36543113
Cell Rep Med. 2023 Jun 20;4(6):101055
pubmed: 37220750
Cancers (Basel). 2020 Mar 29;12(4):
pubmed: 32235397
Nat Med. 2020 Aug;26(8):1271-1279
pubmed: 32572264
Am J Pathol. 2016 May;186(5):1103-13
pubmed: 26993207
Oncologist. 2022 Mar 11;27(3):167-174
pubmed: 35274707
Cancer Cell. 2023 Jun 12;41(6):1103-1117.e12
pubmed: 37207655
Mol Carcinog. 2023 Nov;62(11):1717-1730
pubmed: 37493106
Cancer Genomics Proteomics. 2020 Sep-Oct;17(5):529-541
pubmed: 32859631
Gynecol Oncol. 2021 Dec;163(3):498-505
pubmed: 34602289
Front Oncol. 2015 Jun 30;5:149
pubmed: 26175968
EBioMedicine. 2019 Oct;48:224-235
pubmed: 31648981
J Adv Res. 2023 Jun;48:213-225
pubmed: 36038111
Biochem Biophys Res Commun. 2019 May 28;513(2):340-346
pubmed: 30955858
J Egypt Natl Canc Inst. 2022 Feb 9;34(1):6
pubmed: 35138498
BMC Cancer. 2017 Aug 29;17(1):580
pubmed: 28851311
Histopathology. 2017 Sep;71(3):339-356
pubmed: 28477361
Nature. 2022 Dec;612(7941):778-786
pubmed: 36517593
Ann Diagn Pathol. 2019 Jun;40:30-39
pubmed: 30921622
Mol Oncol. 2020 Nov;14(11):2796-2813
pubmed: 32652647
Genome Biol. 2014 Dec 17;15(12):526
pubmed: 25608477
Nat Commun. 2018 Sep 25;9(1):3917
pubmed: 30254278
Sci Rep. 2021 Sep 27;11(1):19165
pubmed: 34580357
iScience. 2021 Jun 21;24(7):102757
pubmed: 34278265
Clin Cancer Res. 2020 Oct 15;26(20):5411-5423
pubmed: 32554541
Nat Commun. 2021 May 24;12(1):3039
pubmed: 34031395
Cancer Discov. 2016 Dec;6(12):1342-1351
pubmed: 27856443
J Clin Oncol. 2023 Jan 20;41(3):609-617
pubmed: 36082969
Commun Biol. 2023 Jul 3;6(1):688
pubmed: 37400526
Am J Surg Pathol. 2012 Aug;36(8):1170-7
pubmed: 22790858
Cancers (Basel). 2022 Dec 02;14(23):
pubmed: 36497449
Nat Commun. 2022 Oct 26;13(1):6360
pubmed: 36289203
Int J Gynecol Cancer. 2023 Jun 5;33(6):937-943
pubmed: 36948527
Mod Pathol. 2012 Apr;25(4):625-36
pubmed: 22193042
BMC Cancer. 2021 Jun 17;21(1):714
pubmed: 34140011
Br J Cancer. 2020 Apr;122(8):1219-1230
pubmed: 32099096
J Pathol. 2007 Feb;211(3):286-95
pubmed: 17154249
Nanomedicine. 2021 Oct;37:102452
pubmed: 34311116
Hum Pathol. 2018 Oct;80:11-27
pubmed: 29944973
Cell Rep. 2019 Sep 10;28(11):3010
pubmed: 31509758

Auteurs

Eros Azzalini (E)

Department of Medical Sciences (DSM), University of Trieste, 34149 Trieste, Italy.

Giorgio Stanta (G)

Department of Medical Sciences (DSM), University of Trieste, 34149 Trieste, Italy.

Vincenzo Canzonieri (V)

Department of Medical Sciences (DSM), University of Trieste, 34149 Trieste, Italy.
Pathology Unit, Centro di Riferimento Oncologico (CRO) IRCCS, Aviano-National Cancer Institute, 33081 Pordenone, Italy.

Serena Bonin (S)

Department of Medical Sciences (DSM), University of Trieste, 34149 Trieste, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH